1. Home
  2. BCDA vs UPC Comparison

BCDA vs UPC Comparison

Compare BCDA & UPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BCDA
  • UPC
  • Stock Information
  • Founded
  • BCDA N/A
  • UPC N/A
  • Country
  • BCDA United States
  • UPC China
  • Employees
  • BCDA N/A
  • UPC N/A
  • Industry
  • BCDA Biotechnology: Pharmaceutical Preparations
  • UPC Biotechnology: Pharmaceutical Preparations
  • Sector
  • BCDA Health Care
  • UPC Health Care
  • Exchange
  • BCDA Nasdaq
  • UPC Nasdaq
  • Market Cap
  • BCDA 9.4M
  • UPC 13.0M
  • IPO Year
  • BCDA N/A
  • UPC 2021
  • Fundamental
  • Price
  • BCDA $2.87
  • UPC $3.70
  • Analyst Decision
  • BCDA Strong Buy
  • UPC
  • Analyst Count
  • BCDA 1
  • UPC 0
  • Target Price
  • BCDA $60.00
  • UPC N/A
  • AVG Volume (30 Days)
  • BCDA 85.3K
  • UPC 137.1K
  • Earning Date
  • BCDA 08-07-2024
  • UPC 07-30-2024
  • Dividend Yield
  • BCDA N/A
  • UPC N/A
  • EPS Growth
  • BCDA N/A
  • UPC N/A
  • EPS
  • BCDA N/A
  • UPC N/A
  • Revenue
  • BCDA $468,000.00
  • UPC $32,308,735.00
  • Revenue This Year
  • BCDA N/A
  • UPC N/A
  • Revenue Next Year
  • BCDA $436.41
  • UPC N/A
  • P/E Ratio
  • BCDA N/A
  • UPC N/A
  • Revenue Growth
  • BCDA N/A
  • UPC N/A
  • 52 Week Low
  • BCDA $2.62
  • UPC $0.75
  • 52 Week High
  • BCDA $34.80
  • UPC $4.32
  • Technical
  • Relative Strength Index (RSI)
  • BCDA 36.31
  • UPC 62.26
  • Support Level
  • BCDA $2.85
  • UPC $2.87
  • Resistance Level
  • BCDA $3.66
  • UPC $4.11
  • Average True Range (ATR)
  • BCDA 0.30
  • UPC 0.50
  • MACD
  • BCDA 0.07
  • UPC 0.05
  • Stochastic Oscillator
  • BCDA 8.65
  • UPC 68.43

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

About UPC Universe Pharmaceuticals Inc.

Universe Pharmaceuticals Inc is a pharmaceutical company specializing in the manufacturing, marketing, sales and distribution of traditional Chinese medicine derivatives products targeting the elderly with the goal of addressing their physical conditions in the ageing process and promoting their general well-being. The company also sells biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. Its products are under two categories namely treatment and relief for common chronic health conditions in the elderly designed to achieve physical wellness and longevity (Chronic Condition Treatments), and cold and flu medications.

Share on Social Networks: